Chu Saint-Etienne
Saint-Etienne, France
Location status: Recruiting
Location contact
David HUPIN, MD
PRINCIPAL_INVESTIGATOR
Frédéric ROCHE, MD PhD
SUB_INVESTIGATOR
NCT Number: NCT06107452
Cardiac readaptation aims to mitigate cardiovascular risks and enhance the quality of life among coronary patients. Our research laboratory has an international expertise in training optimization in top-athletes and a previous study has demonstrated the efficacy of optimizing cardiac rehabilitation through the power-force-velocity profile (PFVP). The findings exhibited significant improvements in aerobic capacity, muscular strength, and cardiovascular parameters among patients who were trained based on their PFVP. Guided training utilizing heart rate variability (HRV) is also garnering increasing interest as a means to optimize training load and promote recovery
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Saint-Etienne, France
Location status: Recruiting
David HUPIN, MD
PRINCIPAL_INVESTIGATOR
Frédéric ROCHE, MD PhD
SUB_INVESTIGATOR
Our study aims to evaluate the application of HRV in regulating training load based on fatigue levels in cardiac rehabilitation patients utilizing the PFVP framework.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA
a training strategy for subjects whose PFVP is in favour of strength or speed
Time frame: Baseline to 2 months
The root mean square of successive differences in heart rate or RMSSD will be measured from a nocturnal Holter ECG recording at the end of 8 weeks of exercise retraining and compared with the initial pre-training value. weeks of exercise re-training and compared with the initial pre-training value.
Time frame: Baseline to 2 months
VO2 max (ml/min/kg) thanks to 24-hour ECG recording
Time frame: Baseline to 2 months
Assessment of the ANS sympathetic branch thanks to SDNN index value
Time frame: Baseline to 2 months
Assessment of the ANS parasympathetic branch thanks to RMSSSD index value
Time frame: Baseline to 2 months
value of pulse wave propagation velocity
Time frame: Baseline to 2 months
it's a composite outcome :
Time frame: Baseline to 2 months
assessment of PFVP evolution thaks to cycloergometer sprint (Monark, Vansbro)
Time frame: Baseline to 2 months
it's a composite outcome :
Time frame: Baseline to 2 months
it's a composite outcome :
Time frame: Baseline to 2 months
assessment of subjective fatigue thanks to FACIT-F questionary
Time frame: Baseline to 2 months
it's a composite outcome : complete blood biology and relevant inflammatory biomarkers involved in cardiac rehabilitation.
Contact information is provided by the study sponsor or research team.
David HUPIN, MD
CONTACT
(0)4 77 82 84 13 ext. +33
Hélène RAINGARD, CRA
CONTACT
(0)4.77.82.97.03 ext. +33
Centre Hospitalier Universitaire de Saint Etienne
Other
Customization of Cardiac Readaptation Based on Force-velocity Profile and Heart Rate Variability: A Controlled and Randomized Study
Acronym: PROPIU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03881150
Acute Coronary Syndrome, Arterial Occlusive Diseases
Temuco, Araucania, Chile
View Trial DetailsNCT04102410
Acute Coronary Syndrome, Arterial Occlusive Diseases
Saint-Etienne, France
View Trial DetailsNCT07258290
Acute Coronary Syndrome, Angina Pectoris
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04416581
Acute Coronary Syndrome, Arterial Occlusive Diseases
Anyang, South Korea
View Trial Details